Crovalimab vs Eculizumab for Complement Inhibition–Naïve Paroxysmal Nocturnal Hemoglobinuria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Am. J. Hematol 2024 Jun 17;[EPub Ahead of Print], A Röth, G He, H Tong, Z Lin, X Wang, C Chai-Adisaksopha, JH Lee, A Brodsky, C Hantaweepant, TE Dumagay, R Demichelis-Gómez, P Rojnuckarin, J Sun, M Höglund, JH Jang, A Gaya, F Silva, N Obara, RJ Kelly, L Beveridge, S Buatois, S Chebon, B Gentile, P Lundberg, S Sreckovic, JI Nishimura, A Risitano, B HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.